Patient-Focused Treatment Decisions in the Management of Type 2 Diabetes: Expert Perspectives on the Evolving Role of SGLT2 Inhibitors in Cardiovascular and Renal Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2021 to March 1, 2022

 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

Description:
The American Diabetes Association (ADA) estimates that more than 30.3 million people in the United States, or 9.4 percent of the population, have diabetes, and that one in three Americans born in 2019 will develop diabetes sometime during their lifetime. About 90-95% of adults who have diabetes have type 2 Diabetes Mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM doubles a person’s risk for death, and on average individuals with type 2 DM lose 10-15 years of life. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments in Type 2 Diabetes management have given healthcare professionals the ability to shrink this clinical practice gap.

While the prevalence of diabetes continues to rise, a new generation of treatments has become available in the past few years. Continuing education is needed to educate health care professionals about these agents for treatment of T2DM that are effective in lowering A1C levels. Treatments have become available that allow the individualization of T2DM management. There have been many questions in member surveys and past program evaluations about the best practices in regards to the role of combination therapies comprised of SGLT-2 inhibitors in the management of type 2 diabetes. Additionally, new clinical trial data has become available for antidiabetic therapies that have shown improved outcomes for reducing macrovascular risk factors associated with T2DM, including hypertension and heart failure. It is critical that medical directors, clinicians, nurses and other healthcare professionals are educated about this new data and how it will affect the type 2 diabetes treatment paradigm.

Upon completion of this activity, participants will be able to:

  • Describe the pathophysiologic relationships between T2DM and cardiovascular disease (CVD), heart failure (HF), and chronic kidney disease (CKD), including implications for antihyperglycemic treatment

  • Examine the role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular and renal risk factors

  • Discuss the mechanistic profiles, evidence for clinical benefits, and safety concerns associated with SGLT2 inhibitors as treatment options for patients with T2DM

  • Compare the designs and results of large-scale cardiovascular and renal outcomes trials with SGLT2 inhibitors for T2DM

  • Assess the managed care considerations of SGLT2 inhibitors by exploring where these agents fit into the evolving T2DM management paradigm

     

Faculty: Silvio Inzucchi, MD
Professor of Medicine, Fellowship Program Director, Section of Endocrinology
Yale School of Medicine
Clinical Chief, Endocrinology
Medical Director, Yale Diabetes Center
Yale-New Haven Hospital

Disclosure:

Dr. Inzucchi serves on an advisory board for AstraZeneca, Boehringer Ingelheim, Merck, Novo Nordisk, and Sanofi/Lexicon. He has served as a consultant for Abbott, Esperion, and VTV Therapeutics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue